Somatostatin Receptor Imaging of Neuroendocrine Tumors– In the past few decades, the overall incidence of neuroendocrine tumors (NETs) has increased, partly because of improved detection rates. Nevertheless, patients typically experience long delays usually of 5-7 years before diagnosis of NETs, as these tumors display an array of symptoms and there is
a lack of sensitive and specific methods for early detection. Approximately 20% of patients with NETs have metastatic disease at presentation, and in half of those patients the primary tumor is not located at initial imaging.
Somatostatin receptor scintigraphy (SRS) may be informative in imaging patients with newly diagnosed or suspected neuroendocrine tumors. This educational activity discusses the role of the somatostatin hormone and its impact on the body, the relationship between somatostatin receptors (SSTR) and neuroendocrine tumors (NETS), types of NETS, the role of somatostatin receptor scintigraphy (SRS) in the imaging of NETS, case study review, and challenges and pitfalls of SRS.
Describe the structure of somatostatin (SST) hormone and its impact on the body.
Discuss the relationship between somatostatin receptors (SSTR) and neuroendocrine tumors (NETS).
Explain of the relationship between SSTR and somatostatin receptor scintigraphy (SRS) in the imaging of NETS.
Describe the challenges and pitfalls of SRS imaging.
0.75 ARRT CEUs for Radiologic Technicians